Global Gene Silencing Market Size Likely to Reach at a CAGR of 8.2% By 2033

As per the current market research conducted by the CMI Team, the global Gene Silencing Market size is expected to record a CAGR of 8.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 5.2 Billion. By 2033, the valuation is anticipated to reach USD 10.6 Billion.

Gene Silencing Market: Growth Factors and Dynamics

• Advancements in RNA Interference (RNAi): Continuous advancements in RNAi technology, offering more efficient and targeted gene silencing, drive market growth. Improved delivery methods and enhanced specificity contribute to the expanding applications of gene silencing in various fields.

• Rising Incidence of Genetic Disorders: The increasing prevalence of genetic disorders necessitates innovative therapeutic approaches. Gene silencing presents a promising avenue for treating genetic diseases by selectively modulating or suppressing the expression of disease-causing genes, fostering market expansion.

• Expanding Applications in Cancer Therapeutics: Growing research in oncology drives the use of gene silencing techniques for cancer treatment. Targeting specific genes involved in cancer progression allows for more precise and personalized therapeutic interventions, contributing to the market’s dynamic growth.

• Technological Innovations in CRISPR/Cas9: Ongoing developments in the CRISPR/Cas9 system enhance its precision and efficiency in gene editing and silencing. The versatility of CRISPR technology propels its adoption in research, therapeutics, and agricultural applications, driving market growth.

• Increasing Research and Development Activities: Growing investments in research and development activities by pharmaceutical and biotechnology companies fuel innovation in gene silencing. Collaborations, partnerships, and strategic alliances further contribute to the development of novel therapeutics, amplifying market dynamics.

• Rapid Growth in Biotechnology and Pharma Sectors: The expanding biotechnology and pharmaceutical sectors heavily invest in gene silencing research, fostering therapeutic breakthroughs. Increased funding, coupled with a surge in the number of biotech startups, drives the market’s growth as gene silencing technologies become integral to drug discovery and development processes.

• Advancements in Antisense Oligonucleotides (ASOs): Ongoing advancements in ASOs, a key gene silencing method, enhance their specificity and effectiveness. ASOs are gaining prominence in treating genetic disorders, including rare diseases, contributing to the diversification of gene silencing applications and driving market expansion.
• Emerging Applications in Neurological Disorders: Gene silencing technologies are increasingly applied in the treatment of neurological disorders. Targeting specific genes associated with conditions like Alzheimer’s and Parkinson’s disease provides potential avenues for therapeutic interventions, contributing to the market’s growth in addressing unmet medical needs.

Gene Silencing Market: Partnership and Acquisitions

• In 2022, As per FDA data, the Center for Biologics Evaluation and Research (CBER) has regulatory authority over cellular therapy, human gene therapy, and related devices. CBER, empowered by the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, ensures safety, efficacy, and quality, fostering innovation and safeguarding public health.

• In 2023, Libmeldy received approval from the Swiss Agency for Therapeutic Products for treating early-onset metachromatic leukodystrophy. This regulatory milestone highlights the increasing acknowledgement and embrace of gene therapy as a viable and effective treatment avenue for genetic disorders.

Report Scope

Gene Silencing Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Gene Silencing Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Clinical Trials: The pandemic led to disruptions in ongoing clinical trials, affecting the progression of gene silencing therapies. Delays in patient recruitment, regulatory approvals, and data collection impacted the overall development timeline for gene silencing-based treatments.

• Supply Chain Disruptions: The global disruptions in supply chains affected the availability of key components and reagents essential for gene silencing research and development. This impacted the manufacturing and distribution of gene silencing products, creating challenges for market players.

• Resumption of Clinical Trials: As the situation stabilizes, there is a gradual resumption of clinical trials, allowing for the continuation of research and development activities. Revised protocols and enhanced safety measures contribute to the recovery of gene silencing therapies in the pipeline.

• Increased Funding for Research: Governments, private organizations, and investors recognize the importance of gene silencing technologies. Increased funding for research and development initiatives supports the recovery of the market, enabling the exploration of innovative applications and therapeutic avenues.

• Accelerated Digitalization and Virtual Platforms: The pandemic accelerated the adoption of virtual platforms and digital technologies. Virtual collaborations, online conferences, and remote research activities became integral, aiding the gene silencing market’s recovery by facilitating communication, data sharing, and collaborative efforts.

• Strategic Collaborations and Partnerships: Industry players are increasingly engaging in strategic collaborations and partnerships to pool resources, share expertise, and expedite research efforts. Such alliances contribute to the accelerated recovery of the gene silencing market by fostering innovation and enhancing product development.

• Diversification of Supply Chains: Lessons from supply chain disruptions during the pandemic prompted companies to diversify their supply chains. Establishing resilient and diversified supply networks ensures a more stable flow of essential components, mitigating risks and contributing to the market’s recovery.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Gene Silencing Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Gene Silencing Market:

• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Dicerna Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Quark Pharmaceuticals Inc.
• Benitec Biopharma Limited
• GenScript Biotech Corporation
• GeneCopoeia Inc.
• Sirion Biotech GmbH
• Oxford BioMedica plc
• AstraZeneca plc
• Merck & Co. Inc.
• Novartis International AG
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Others

The Gene Silencing Market is segmented as follows:

By Gene Silencing Method

• RNA Interference (RNAi)
• Antisense Oligonucleotides (ASOs)
• CRISPR/Cas9-Based Gene Silencing
• Others

By Application

• Cancer Therapeutics
• Neurological Disorders
• Genetic Disorders
• Infectious Diseases
• Others

By End-Users

• Pharmaceutical and Biotechnology Companies
• Research Institutes and Academic Centers
• Hospitals
• Clinics
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America